SONN Sonnet BioTherapeutics Holdings Company Short-Term Debt

sonnetbio.com - graphic logo of issuer SONN

Sonnet BioTherapeutics (SONN) retains its immuno-oncology expert staff through stock options, having optimized its team. Changes in short-term liabilities illustrate borrowing dynamics, with the parameter stabilizing at 0.00. The laboratory develops targeted immunomodulators to combat metastases. However, management's high reliance on external funding and binary risks make pipeline development critically dependent on successful fundraising.

SONN Sonnet BioTherapeutics Holdings Inc. Short-Term Debt (07/04/2022 - 12/13/2025)

Analytical breakdowns and data insights for company Sonnet BioTherapeutics Holdings, Inc. (SONN)

- current quotes and average value forecast:
Price Chart Sonnet BioTherapeutics Holdings Inc.|SONN - Average Forecast Price
- market capitalization data:
Market Value Sonnet BioTherapeutics Holdings|SONN - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Sonnet BioTherapeutics|SONN - Total Stockholders' Equity|Market Capitalization to Book Value Ratio sonnetbio.com|SONN - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Sonnet BioTherapeutics|SONN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Sonnet BioTherapeutics Holdings Inc.|SONN - Aggregate Debt Obligations|Debts to Book Capitalization Sonnet BioTherapeutics Holdings|SONN - Long-Term Debt Volume|Company Short-Term Debt Sonnet BioTherapeutics|Quick Liquidity sonnetbio.com
- earnings and multiples data:
SONN - Net Income
General company analysis:sonnetbio.com (SONN)
Flagship merchandise of Sonnet BioTherapeutics

Investment analysis of Sonnet BioTherapeutics (SONN) requires a precise liquidity assessment, where the company's short-term liabilities reflect the volume of loans maturing within one year. This indicator allows for an evaluation of interest overpayment risks when scaling production via CDMO partners, confirming the efficiency of utilizing external capacities in New Jersey to optimize capital structure and minimize debt load.

Competitors of Sonnet BioTherapeutics

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts Immix Biopharma Inc. IMMX|ALXO - Company Short-Term Debt|CUE (Cue Biopharma Inc.) - Company Short-Term Indebtedness|pdsbiotech.com (PDSB) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)